MedTrace Logo

Genotype-Guided Warfarin Therapy Trial

NCT00904293 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2016-05-06

No results posted yet for this study

Summary

The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.

Conditions

Interventions

OTHER

Genotype-guided dose determination

Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.

OTHER

Non-genotype guided warfarin dosing

Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.

Sponsors & Collaborators

  • UNC Institute for Pharmacogenomics and Individualized Therapy

    collaborator UNKNOWN

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Daniel E Jonas, MD, MPH · UNC Institute for Pharmacogenomics and Individualized Therapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904293 on ClinicalTrials.gov